Compare CYTK & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | BIO |
|---|---|---|
| Founded | 1997 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 10.1B |
| IPO Year | 2004 | 1994 |
| Metric | CYTK | BIO |
|---|---|---|
| Price | $62.30 | $351.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 23 | 3 |
| Target Price | $109.40 | ★ $335.00 |
| AVG Volume (30 Days) | ★ 2.0M | 229.8K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 142.61 |
| EPS | ★ N/A | N/A |
| Revenue | $13,368,000.00 | ★ $2,583,200,000.00 |
| Revenue This Year | $72.63 | N/A |
| Revenue Next Year | $181.06 | $2.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.65 |
| 52 Week Low | $54.30 | $236.73 |
| 52 Week High | $88.31 | $396.23 |
| Indicator | CYTK | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 38.36 |
| Support Level | $59.21 | $284.88 |
| Resistance Level | $67.65 | $391.87 |
| Average True Range (ATR) | 2.01 | 12.91 |
| MACD | 0.31 | -2.15 |
| Stochastic Oscillator | 34.67 | 1.96 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.